Why Novo/Eli Lilly stock have bad ratings when there’s a big demand for ozempic

I see the ratings from several firms giving these two companies very low rankings stock wise.
These two are the companies that produce ozempic/etc and it seems they can’t keep up with demand, not to mention future demand for obesity.

I couldn’t find much info stating the low ratings, and some are behind paywall articles or have to sign up etc to a service.

Obviously by the level of my question it’s not like I think I’ve figured out the next “to the moon” stock but trying to understand why these two companies would not be showing much better in these firms analysis or there’s more positive talk from traders.

Edit: that was fast thanks. The growth has already happened and some analysts see them as now overpriced.